Chemists at the University of Bath have worked out how small changes to the molecular structure of azulene-based fluorescent probes alter their color and brightness, offering a design guide for future tools used to detect diseases. The work, led by Professor Simon Lewis, Professor Tony James and Dr Dan Pantos, was published in Organic Chemistry Frontiers and funded by the EPSRC.
Azulene is a naturally occurring blue compound found in certain mushrooms and corals, and it is already used in some skincare products to calm irritation. What makes it useful to imaging scientists is that it absorbs light at one wavelength and emits it at another, which lets it act as a fluorophore, the part of a probe that glows. A fluorescent probe pairs that glow with a receptor that binds to a specific substance inside a cell, so researchers can watch biological processes under a microscope.
The team built a family of these probes, which they named the AzuFluor platform. Postdoctoral researcher Dr Chiara Faverio synthesized and analyzed a wide range of new azulene derivatives, allowing the group to systematically test how subtle structural changes shift fluorescence color and brightness. One molecule they developed was five times brighter than the original azulene molecule.
The program was aimed at giving researchers new ways to observe molecular events inside living cells in real time, with the stated targets including Alzheimer's disease, Parkinson's disease, cancer and asthma. Dr Faverio described the probes as acting like molecular beacons that light up in response to specific biological targets, a framing that explains why brightness and color control matter for seeing processes that would otherwise be invisible.
The main contribution here is a set of design rules rather than a finished diagnostic. The researchers describe the work as revealing the molecular features that control brightness and emission, which gives chemists a clearer starting point for building more sensitive probes. The source does not report testing these probes in patients or in disease models, so the step from this chemistry to clinical use remains ahead.